NYSE Arca · IGC
IGC Pharma, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IGC: Nov 13, 2026
IGC Pharma, Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.02. The reported EPS for the same quarter last year was $-0.02.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Dec 2026 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Mar 2027 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Jun 2027 | $-0.02 | $-0.02 | $-0.02 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks · RTTNews · NASDAQ.com- Fintel · Mar 27, 3:13 PM EDTIGC Pharma (IGC) Price Target Increased by 10.34% to 4.08The average one-year price target for IGC Pharma (NYSEAM:IGC) has been revised to $4.08 / share. This is an increase of 10.34% from the prior estimate of $3.70 dated February 21, 2026. The price target is an average of many targets provided by analysts. The la
- Zacks · Mar 19, 5:45 PM EDTelectroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue EstimateselectroCore (ECOR) delivered earnings and revenue surprises of +1.45% and -0.18%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 18, 5:25 PM EDT4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +180.75% and +147.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 5, 7:05 AM ESTMerck KGaA (MKKGY) Lags Q4 Earnings EstimatesMerck KGaA (MKKGY) delivered earnings and revenue surprises of -40.43% and +0.69%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Dec 10, 5:00 AM ESTIGC Pharma Achieves 65% Enrollment In Phase 2 CALMA Trial For Alzheimer's Agitation(RTTNews) – IGC Pharma, Inc. (IGC), a clinical-stage biotechnology company, has announced that it has reached 65% patient enrolment in its ongoing Phase 2 CALMA trial evaluating IGC-AD1 for the treatment of agitation in Alzheimer's disease.
- Fintel · Dec 9, 7:05 PM ESTAscendiant Capital Maintains IGC Pharma (IGC) Buy RecommendationFintel reports that on December 9, 2025, Ascendiant Capital maintained coverage of IGC Pharma (NYSEAM:IGC) with a Buy recommendation. Analyst Price Forecast Suggests 1,171.49% Upside
- Zacks · Nov 14, 5:30 PM ESTIGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue EstimatesIGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of 0.00% and -56.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
- NASDAQ.com · Nov 14, 4:00 PM ESTPre-Market Earnings Report for November 17, 2025 : HTHT, ARMK, YMM, JJSF, JKS, CRGO, ARBE, NRXP, IGC, VRMEThe following companies are expected to report earnings prior to market open on 11/17/2025. Visit our Earnings Calendar for a full list of expected earnings releases.H World Group Limited (HTHT)is reporting for the quarter ending September 30, 2025. The hotel company's consensus
- Zacks · Nov 13, 5:20 PM ESTProfound Medical Corp. Reports Narrower Q3 Loss, Revenue SurgeProfound Medical (PROF) delivered earnings and revenue surprises of +31.58% and +0.74%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Nov 12, 5:15 PM ESTLyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue EstimatesLyra Therapeutics (LYRA) delivered earnings and revenue surprises of +43.48% and -77.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Nov 10, 5:20 PM ESTTheravance Biopharma (TBPH) Q3 Earnings and Revenues Beat EstimatesTheravance Bio (TBPH) delivered earnings and revenue surprises of +233.33% and +2.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Nov 6, 7:10 AM ESTEsperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue EstimatesEsperion Therapeutics (ESPR) delivered earnings and revenue surprises of -77.78% and +4.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for IGC Pharma, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.